AFMDQ — Affimed NV Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.57m
- €8.28m
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million
Brief: Affimed Appoints Shawn M. Leland As Chief Executive Officer
Brief: Affimed Gets FDA's Fast Track Designation For Combination Therapy Of Afm24 With Atezolizumab For Egfr Wild-Type Non-Small Cell Lung Cancer
Brief: Affimed Announces Positive Early Efficacy And Progression Free Survival Results Of AFM24-102 Study In EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed rises on positive data from cancer therapy trials
Affimed rating cut to 'hold' on lack of pipeline development clarity
Affimed rises after pricing upsized stock deal
Brief: Affimed Says Announced Pricing Of Upsized $90 Million Public Offering Of Common Shares
U.S. STOCKS ON THE MOVE-Tesla, Bluebird Bio, Zhihu, Talkspace
U.S. RESEARCH ROUNDUP-Contextlogic, McCormick & Company, Novocure
Affimed falls on $100 mln stock deal
Affimed NV: Up on dosing first patient in early-stage cancer therapy study
Brief: Affimed NV Expects Coronavirus Pandemic To Impact Clinical Trials
Nasdaq Trade Halt Market Wide Circuit Breaker Halt: LEVEL 1 AT 08:34 AM
U.S. RESEARCH ROUNDUP-Bunge, Lululemon Athletica, Welltower
U.S. RESEARCH ROUNDUP-Booking Holdings, New York Times, O'Reilly Automotive